Shares of Cerus Corp. (NASDAQ:CERS) saw strong trading volume on Friday . 1,242,206 shares changed hands during trading, an increase of 5% from the previous session’s volume of 1,179,011 shares.The stock last traded at $6.40 and had previously closed at $6.36.

A number of research analysts have recently weighed in on the stock. FBR & Co restated a “buy” rating on shares of Cerus Corp. in a report on Wednesday, May 4th. Cantor Fitzgerald restated a “buy” rating and set a $8.00 price target on shares of Cerus Corp. in a report on Thursday, March 10th. BTIG Research restated a “buy” rating on shares of Cerus Corp. in a report on Monday, March 14th. Finally, Robert W. Baird restated an “outperform” rating and set a $9.00 price target on shares of Cerus Corp. in a report on Wednesday, March 16th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $8.90.

The firm has a 50 day moving average price of $5.92 and a 200-day moving average price of $5.80. The firm’s market capitalization is $656.03 million.

Cerus Corp. (NASDAQ:CERS) last released its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. During the same quarter in the previous year, the business earned ($0.17) EPS. The company had revenue of $7.60 million for the quarter, compared to analyst estimates of $8.29 million. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. On average, analysts predict that Cerus Corp. will post ($0.65) EPS for the current year.

Other institutional investors have added to or reduced their stakes in the company. California State Teachers Retirement System increased its position in Cerus Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 176,709 shares of the company’s stock valued at $1,117,000 after buying an additional 3,126 shares during the period. EAM Investors LLC purchased a new stake in shares of Cerus Corp. during the fourth quarter worth about $1,139,000. Rail Splitter Capital Management LLC increased its stake in shares of Cerus Corp. by 19.0% in the fourth quarter. Rail Splitter Capital Management LLC now owns 832,722 shares of the company’s stock worth $5,263,000 after buying an additional 132,970 shares during the last quarter. Stephens Inc. AR increased its stake in shares of Cerus Corp. by 11.3% in the fourth quarter. Stephens Inc. AR now owns 1,112,665 shares of the company’s stock worth $7,032,000 after buying an additional 113,238 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Cerus Corp. by 25.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,901,666 shares of the company’s stock worth $30,979,000 after buying an additional 1,007,430 shares during the last quarter.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.